The Meningitis Foundation Adds Voice To Calls For Pharmac To Overhaul Its Approach To Funding Decisions

A new study commissioned by the Multiple Sclerosis Society of New Zealand (MSNZ), analysed the cost-effectiveness of Ocrelizumab, which received Pharmac funding as a treatment for primary progressive multiple sclerosis (PPMS) in New Zealand last ...